NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
IPO Year:
Exchange: NASDAQ
Website: neogenomics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2024 | $26.00 | Buy | Craig Hallum |
| 12/29/2023 | $25.00 → $21.00 | Buy | BTIG Research |
| 8/21/2023 | $18.00 | Equal-Weight → Overweight | Stephens |
| 5/16/2023 | Outperform → Mkt Perform | Raymond James | |
| 5/9/2023 | $25.00 | Neutral → Buy | BTIG Research |
| 2/24/2023 | $20.00 | Hold → Buy | The Benchmark Company |
| 2/1/2023 | $15.00 | Hold → Buy | Needham |
| 8/26/2022 | Buy → Hold | The Benchmark Company | |
| 8/22/2022 | Buy → Hold | Needham | |
| 6/3/2022 | $13.00 | Overweight | Piper Sandler |
SC 13G - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G - NEOGENOMICS INC (0001077183) (Subject)
SC 13G - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
10-Q - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
S-8 - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
10-Q - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
ARS - NEOGENOMICS INC (0001077183) (Filer)
DEFA14A - NEOGENOMICS INC (0001077183) (Filer)
DEF 14A - NEOGENOMICS INC (0001077183) (Filer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
Approval Broadens Patient Access to Company's NGS Test for More Accurate Diagnostic and Prognostic Pan-Tumor Cancer Results NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that the New York State Department of Health (NYSDOH) has granted the company conditional approval for its Neo Comprehensive Solid Tumor assay and NeoTYPE® DNA & RNA Lung, allowing for immediate commercial access in the state of New York. These next-generation sequencing (NGS) tests deliver better diagnostic value and cost-effectiveness than single gene testing and direct the first-line treatment of diverse solid tumors, including non-small cell lung cancer. New York State is
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior
New test fills unmet need for faster AML biomarker testing, expanding NeoGenomics' broad oncology testing portfolio NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today the launch of AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia (AML). "AML Express enhances our hematologic portfolio by addressing the clinical need for faster testing that informs critical treatment decisions," said Chris Smith, CEO of NeoGenomics. "This new test offers physicians a more efficient solution that delivers patient-specific insights to guide precise treatment strate
Company will host business update call on Sept. 24, 2024, at 8:30 a.m. ET NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today issued the following statement in response to inquiries: NeoGenomics has cleared the feasibility stage with a new version of its RaDaR® technology and has resolved litigation with Natera regarding RaDaR 1.0. The Company will host a business update conference call and webcast on Tuesday, Sept. 24, 2024, beginning at 8:30 a.m. Eastern Time. The accelerated progress of the new RaDaR technology provided the Company the opportunity to negotiate a resolution with Natera as to RaDaR 1.0. The settlement, while confidential, is not material t
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, September 13-17 (booth #438). NeoGenomics' data offers key insights into circulating tumor DNA (ctDNA) analysis and next-generation sequencing (NGS), focusing on their role in early diagnosis and treatment optimization. "Emerging technologies leveraging ctDNA and NGS are increasing our ability to identify cancers in high-risk patients, which was previously beyond reach," said Dr. Nathan Montgomery, Vice President of Medical Services at NeoGenomics. "Collectively, our findings demonstrate the potential
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will attend the Morgan Stanley 22nd Annual Global Healthcare Conference. Chris Smith, Chief Executive Officer, Jeff Sherman, Chief Financial Officer, and Warren Stone, Chief Commercial Officer, will participate in an in-person fireside chat on Friday, Sept. 6, 2024, at 10:45 a.m. ET in New York City. The presentation will be webcast live and accessible online via this link. A replay will be available on the Investor Relations section of the Company's website at ir.neogenomics.com. About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the mo
Second Quarter Revenue Increased 12% to $165 Million Raising Revenue Guidance $655 to $667 Million and Adjusted EBITDA to $33 to $37 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2024. Second Quarter 2024 Highlights As Compared To Second Quarter 2023 Consolidated revenue increased 12% to $165 million Clinical Services revenue increased 15% to $141 million Advanced Diagnostics revenue decreased 3% to $23 million Net loss decreased 23% to $19 million Adjusted EBITDA increased 630% to positive $11 million "The second quart
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that Fort Myers' Mayor, Kevin Anderson, will be dedicating June as NeoGenomics' Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in Fort Myers, NeoGenomics serves over 600,000 patients each year and is on a mission to serve one million patients annually by 2028. "With studies suggesting that 1 in 2 men and 1 in 3 women will be diagnosed with cancer in their lifetime,1 our role as a leading oncology testing services company is more crucial than ever," said Chris Smith, CEO at NeoGenomics. "Receiving this proclamation from the mayor is a test
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior
Company will host business update call on Sept. 24, 2024, at 8:30 a.m. ET NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today issued the following statement in response to inquiries: NeoGenomics has cleared the feasibility stage with a new version of its RaDaR® technology and has resolved litigation with Natera regarding RaDaR 1.0. The Company will host a business update conference call and webcast on Tuesday, Sept. 24, 2024, beginning at 8:30 a.m. Eastern Time. The accelerated progress of the new RaDaR technology provided the Company the opportunity to negotiate a resolution with Natera as to RaDaR 1.0. The settlement, while confidential, is not material t
Second Quarter Revenue Increased 12% to $165 Million Raising Revenue Guidance $655 to $667 Million and Adjusted EBITDA to $33 to $37 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2024. Second Quarter 2024 Highlights As Compared To Second Quarter 2023 Consolidated revenue increased 12% to $165 million Clinical Services revenue increased 15% to $141 million Advanced Diagnostics revenue decreased 3% to $23 million Net loss decreased 23% to $19 million Adjusted EBITDA increased 630% to positive $11 million "The second quart
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior
First Quarter Revenue Increased 14% to $156 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024. Highlights Consolidated revenue increased 14% to $156 million Clinical Services revenue increased 17% to $135 million Advanced Diagnostics revenue decreased 3% to $22 million Net loss decreased 12% to $27 million Adjusted EBITDA was positive $3 million, an increase of 149% or $11 million "NeoGenomics had a strong start to 2024, with first quarter revenue growth of 14% yea
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its first quarter 2024 financial results on Tuesday, April 30, 2024. Company management will host a webcast and conference call that morning at 8:30 a.m. Eastern Time to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (877) 545-0523 (domestic) or (973) 528-0016 (international) at least five minutes prior to the call. The part
Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023. Highlights Fourth quarter consolidated revenue increased 12% to $156 million; Full year consolidated revenue increased 16% to $592 million Fourth quarter Clinical Services revenue increased 20% to $130 million; Full year Clinical Services revenue increased 18% to $496 million Fourth quarter Advanced Diagnostics revenue decreased 17% to $25 million; Full year
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024. Company management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to
Third Quarter Revenue Increased 18% to $152 MillionFORT MYERS, FL / ACCESSWIRE / November 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2023 as compared to September 30, 2022.Third Quarter 2023 HighlightsQ3 2023 ResultsConsolidated revenue increased 18% to $152 millionClinical Services revenue increased 20% to $128 millionAdvanced Diagnostics revenue increased 8% to $24 millionNet loss decreased 50% to $19 millionAdjusted EBITDA increased 129% to positive $3 millionRaised Full-Year 2023 GuidanceRaised revenue guidance to a range of $585 million - $592 million,
FT. MYERS, FL / ACCESSWIRE / October 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its third quarter 2023 financial results on Monday, November 6, 2023. Company management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call.To access the live call via telephone, dial (888) 506-0062 (domestic) or (973)
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31–June 4 (booth #31093).
The Q1 earnings report for NeoGenomics (NASDAQ:NEO) was released on Tuesday, April 30, 2024 at 07:30 AM. Here's what investors need to know about the latest announcement. Earnings NeoGenomics beat estimated earnings by 60.0%, reporting an EPS of $-0.02 versus an estimate of $-0.05. Revenue was up $19.02 million from the same period last year. Analysis of Past Earnings Last quarter the company beat on EPS by $0.05 which was followed by a 12.0% increase in the share price the next day. Here's a look at NeoGenomics's past performance: Quarter Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 EPS Estimate -0.05 -0.02 -0.08 -0.11 -0.15 EPS Actual -0.02 0.03 0 -0.05 -0.09 Revenue Estimate 149.89M
BTIG analyst Mark Massaro maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $23 to $21.
TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $21 to $20.
Craig-Hallum analyst Alex Nowark assumes NeoGenomics (NASDAQ:NEO) with a Buy rating and announces Price Target of $26.
Benchmark analyst Bruce Jackson reiterates NeoGenomics (NASDAQ:NEO) with a Buy and maintains $18 price target.
Ratings for NeoGenomics (NASDAQ:NEO) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 1 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.5, a high estimate of $24.00, and a low estimate of $19.00. This current average reflects an increase of 2.5% from t
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $24 to $19.
Craig Hallum resumed coverage of NeoGenomics with a rating of Buy and set a new price target of $26.00
BTIG Research reiterated coverage of NeoGenomics with a rating of Buy and set a new price target of $21.00 from $25.00 previously
Stephens upgraded NeoGenomics from Equal-Weight to Overweight and set a new price target of $18.00
Raymond James downgraded NeoGenomics from Outperform to Mkt Perform
BTIG Research upgraded NeoGenomics from Neutral to Buy and set a new price target of $25.00
The Benchmark Company upgraded NeoGenomics from Hold to Buy and set a new price target of $20.00
Needham upgraded NeoGenomics from Hold to Buy and set a new price target of $15.00
The Benchmark Company downgraded NeoGenomics from Buy to Hold
Needham downgraded NeoGenomics from Buy to Hold
Piper Sandler initiated coverage of NeoGenomics with a rating of Overweight and set a new price target of $13.00
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year
FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors.The Board has elected three new independent board members to join the board effective June 29, 2023. Elizabeth Floegel, Chief Information & Digital Officer of Numotion, a complex rehabilitation technology provider, will be a member of the Audit & Finance and Compliance Committees. Neil Gunn, former Chief Executive Officer of IDbyDNA, a developer of metagenomic technology for infectious disease testing and pathogen surveillance which was
FT. MYERS, FL / ACCESSWIRE / November 7, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, has appointed David B. Perez - a veteran leader in medical devices and health care services - to serve on its Board of Directors, effective November 3, 2022."I am thrilled to welcome David to our Board of Directors. With his proven record in growing and scaling highly-regulated companies, David brings valuable experience and insights to NeoGenomics as the company continues to expand its testing and information services to transform cancer care," said Lynn Tetrault, Chair of the Board of NeoGenomics.With 40 years of global executive lead
FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Lynn Tetrault, Esq., the current Executive Chair and Principal Executive Officer, as Chair of the Board and Interim CEO as of May 12, 2022.Ms. Tetrault has been serving as Executive Chair since March when the Company's CEO agreed to step down. Ms. Tetrault was overseeing the Interim Office of the CEO to provide seamless leadership continuity and operational management of the Company while the Board conducts a search for the Company's permanent CEO."Lynn's leadershi
FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata and the departure of former President of Inivata Dr. Clive Morris. Vishal will officially join NeoGenomics on May 23, 2022 and Dr. Morris will assist in the leadership transition over an appropriate handover period.Vishal Sikri has over 20 years of experience in the somatic diagnostics space and most recently was President of Oncology at Invitae. Prior to Invitae, Vishal served as U.S. General Manager for Biocartis l
Board Appoints Executive Chair and Interim Office of the CEOAnticipates First Quarter Results Below Guidance and Withdraws 2022 GuidanceFT. MYERS, FL / ACCESSWIRE / March 28, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that the Board of Directors (the "Board") and Mark Mallon, Chief Executive Officer, have agreed that Mr. Mallon will step down as CEO and member of the Board, effective immediately. This mutual agreement was not the result of any disagreements about strategy with management or the Board, inappropriate action by CEO, or any violation of compan
FT. MYERS, FL / ACCESSWIRE / February 14, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has announced that Shashikant Kulkarni, M.S (Medicine)., Ph.D., MBA, FACMG will be joining the NeoGenomics executive team as Executive Vice President for Research & Development and Chief Scientific Officer on March 7th.Dr. Kulkarni most recently served as Chief Scientific Officer and Senior Vice President of Innovation and Emerging Business at Baylor Genetics. He also served as a tenured professor and Vice Chairman for Research in the number one Genetics Department in the US, Department of Molecular and
Inivata Appoints David Eberhard MD, PhD as Chief Medical Officer Research Triangle Park, NC, USA and Cambridge, UK, 13 December 2021 -- Inivata, a leader in liquid biopsy, today announced the appointment of David Eberhard MD, PhD as Chief Medical Officer (CMO). David will oversee the clinical and strategic development of Inivata's liquid biopsy tests with a particular focus on its RaDaR™ assay for the detection of minimal residual disease (MRD). David is a seasoned healthcare executive, bringing over 20 years' experience in the research and development of oncology therapeutics, biomarkers, and diagnostics. He joins Inivata from Illumina, where he served as Senior Medical Director, Oncol
FT MYERS, FL / ACCESSWIRE / December 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced the appointment of David Eberhard MD, PhD as Chief Medical Officer (CMO) of its liquid biopsy focused subsidiary Inivata Limited ("Inivata"). David will report to Inivata President Clive Morris and will oversee the clinical and strategic development of Inivata's liquid biopsy tests with a particular focus on its RaDaR™ assay for the detection of minimal residual disease (MRD).David is a seasoned healthcare executive, bringing over 20 years' experience in the research and development of onc
FT. MYERS, FL / ACCESSWIRE / November 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has appointed Dave Daly to serve on its Board of Directors.Dave Daly joined our Board of Directors effective November 10, 2021. Mr. Daly currently serves as the President and Chief Operating Officer at Singular Genomics, a novel next generation sequencing and multi-omics technology platform company. Prior to Singular Genomics, Mr. Daly served as Chief Executive Officer at Thrive Earlier Detection, a liquid biopsy focused cancer screening company that was acquired by Exact Sciences Corporation for $2.15 B